Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol-Myers Squibb auf Einkaufstour! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Bristol-Myers…

5 Things to Know Before The Stock Market Opens

Pharmaceutical giant Bristol Myers Squibb is buying Karuna Therapeutics for $14 billion to expand its psychiatric drugs portfolio and Nike…

Karuna Therapeutics soars after $14 billion takeover by Bristol Myers

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimers drugmaker Karuna Therapeutics for…

Übernahme-Hammer vor Weihnachten: Bristol-Myers Squibb mit Milliarden-Deal

Das Übernahmekarussell im Biotech-Sektor dreht sich weiter. Am letzten Handelstag vor Weihnachten wird die Übernahme von Karuna Therapeutics durch Bristol-Myers…

Übernahme-Hammer vor Weihnachten: Bristol-Myers Squibb mit Milliarden-Deal

Das Übernahmekarussell im Biotech-Sektor dreht sich weiter. Am letzten Handelstag vor Weihnachten wird die Übernahme von Karuna Therapeutics durch Bristol-Myers…

Milliardendeal: Bristol-Myers will Biopharmaunternehmen Karuna kaufen

NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol-Myers Squibb will seinen Konkurrenten Karuna Therapeutics übernehmen. Die…

Bristol Myers to buy Karuna Therapeutics for $14 billion

Bristol Myers Squib agreed to buy Karuna Therapeutics for $14 billion on Friday, gaining a promising experimental schizophrenia drug.…

Bristol-Myers Squibb to acquire Karuna for $14 billion

Bristol-Myers Squibb to acquire Karuna for $14 billion - WSJ…

The Zacks Analyst Blog Highlights Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar

Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar are included in this Analyst Blog.…

Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now

…

Better Dividend Stock: Bristol Myers Squibb or Merck?

These two pharma stocks have sizable dividend yields. Which is the better buy right now?…

Better Dividend Stock: Bristol Myers Squibb or Merck? @themotleyfool #stocks $BMY $MRK $^GSPC

These two pharma stocks have sizable dividend yields. Which is the better buy right now?…

Is Bristol Myers Squibb Stock a Buy Now?

The answer might depend on the kind of investor you are.…

Global Gene Therapy Market Size to Worth USD 49.21 Billion by 2032 | CAGR of 20.46%

The Global Gene Therapy Market Size was valued at USD 7.65 Billion in 2022 and the Worldwide Gene Therapy Market…

Bristol Myers Squibb Co. stock falls Thursday, underperforms market

Shares of Bristol Myers Squibb Co. slipped 0.75% to $51.47 Thursday, on what proved to be an all-around great trading…

Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock

…

ALLR: Stenoparib Clinical Update

By John Vandermosten, CFA NASDAQ:ALLR Early Results - Phase II Stenoparib Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…

: Bristol Myers adds $3 billion to share buyback program to boost total to about $5 billion

Bristol Myers Squibb Co. BMY announced an additional $3 billion share buyback program on Thursday, boosting the full authorization to…

: Bristol Myers Squibb raises dividend by 5.3%

Bristol Myers Squibb Co. BMY said late Wednesday that its board has declared a quarterly dividend of 60 cents a…

Multiple Myeloma Market revenue to surpass USD 71 Billion by 2035, says Research Nester

Major multiple myeloma market players include Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals…

Global Melanoma Therapeutics Market Size To Worth USD 12.35 Billion By 2032 | CAGR of 9.4%

The Global Melanoma Therapeutics Market Size was valued at USD 5.03 Billion in 2022 and the Worldwide Melanoma Therapeutics Market…

Bristol Myers Squibb new CEO buys company shares

…

Bristol Myers Squibb CEO Chris Boerner Buys Up Stock

…

Fortunes Can Be Made With Bristol-Myers Squibb

Taking a closer look at one of the largest companies in the pharmaceutical industry…

[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

Avidity Biosciences leaps on Bristol-Myers research tie-up

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co...…

Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better

…

: Avidity’s stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

Avidity Biosciences Inc. RNA said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal…

Global Non-Hodgkin Lymphoma Therapeutics Market Size To Worth USD 16.64 Billion by 2032 | CAGR of 7.8%

The Global Non-Hodgkin Lymphoma Therapeutics Market Size was valued at USD 7.85 Billion in 2022. The Worldwide Non-Hodgkin Lymphoma Therapeutics…

Bristol-Myers Squibb: The Patent Expiry Challenge

…

Bristol Myers Squibb: A Bitter Pill But Still A Buy

…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis

The hypertrophic cardiomyopathy market dynamics are anticipated to change during the forecast period (2023–2032) due to the expected launch of…

Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment

The stock isnt nearly as risky as its low valuation suggests.…

Bristol-Myers Squibb Company (BMY) Management Presents at 2023 UBS BioPharma Conference (Transcript)

…

dpa-AFX ProFeed